NCT00176020Unknown1 期
Double-Blind, Randomized, Placebo-Controlled, Single-Center, 2 Treatment, 3-Way Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 Mg Nicotinic Acid as Tablets in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 18
研究概览
简要总结
The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be:
- Treatment A: 500 mg nicotinic acid (Niacor(R))
- Treatment B: Niacor(R) Placebo
Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Good state of health physically and mentally
排除标准
- •Treatment with any other investigational product in the last 60 days before the day of randomization into the study
- •Regular use of medication in the last 60 days before the day of randomization into the study except of oral contraceptives in female participants
- •Treatment in the 60 days before the day of randomization into the study with any drug known to have a well-defined potential for toxicity to a major organ, or any substance which is known to induce or inhibit hepatic drug metabolism (including general anesthetics)
- •Any drug intake (including over-the-counter remedies) in the 2 weeks before the day of randomization into the study, unless the investigator considers a drug intake to be clinically irrelevant for the purpose of this study
- •Any acute or chronic illness or clinically relevant findings in the pre-study examination
- •Presence, history or sequelae of gastrointestinal (e.g. peptic ulcer), liver or kidney disease, or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
- •History of hypersensitivity to the investigational product
- •History or presence of abnormalities of the vascular bed
- •History or presence of a dermatologic disease or skin lesions, particular in the area chosen for flush measurement
- •History of allergy or hypersensitivity to other drugs or to food constituents
- •History of other allergic diseases or hypersensitivity, unless the investigator considers it to be clinically irrelevant for the purpose of this study
- •Blood donation of > 400 ml in the 60 days before the day of randomization into the study
- •Positive result in urine screen for drugs of abuse or in alcohol breath test
- •Known or suspected to be drug-dependent, including consumption of > 30 g alcohol per day
- •Pregnancy or lactation
- •Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
- •Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- •Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study
研究者
相似试验
已完成
1 期
Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of a Single Oral Repeated Dose of 500 mg Nicotinic Acid as Tablets in Healthy SubjectsHealthy SubjectsNCT01258491Heidelberg University18
终止
2 期
A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With SimvastatinHypercholesterolemiaNCT00466869OBEcure Ltd.30
已完成
1 期
A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White SubjectsHealthy VolunteersNCT02039089Eisai Inc.32
已完成
1 期
Drug Interaction Study to Investigate Co-administration of GW642444M With KetoconazolePulmonary Disease, Chronic ObstructiveNCT00866515GlaxoSmithKline20
招募中
1 期
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD PatientsDiabetic Kidney DiseaseNCT06666283Alebund Pharmaceuticals18